Evoke Pharma Retained Earnings (Accumulated Deficit) 2012-2024 | EVOK
Evoke Pharma retained earnings (accumulated deficit) from 2012 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Evoke Pharma Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$-123 |
| 2022 |
$-116 |
| 2021 |
$-107 |
| 2020 |
$-99 |
| 2019 |
$-86 |
| 2018 |
$-79 |
| 2017 |
$-71 |
| 2016 |
$-59 |
| 2015 |
$-48 |
| 2014 |
$-36 |
| 2013 |
$-23 |
| 2012 |
$-20 |
| 2011 |
$-18 |
Evoke Pharma Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-09-30 |
$-128 |
| 2024-06-30 |
$-126 |
| 2024-03-31 |
$-125 |
| 2023-12-31 |
$-123 |
| 2023-09-30 |
$-121 |
| 2023-06-30 |
$-120 |
| 2023-03-31 |
$-118 |
| 2022-12-31 |
$-116 |
| 2022-09-30 |
$-114 |
| 2022-06-30 |
$-112 |
| 2022-03-31 |
$-110 |
| 2021-12-31 |
$-107 |
| 2021-09-30 |
$-106 |
| 2021-06-30 |
$-104 |
| 2021-03-31 |
$-101 |
| 2020-12-31 |
$-99 |
| 2020-09-30 |
$-97 |
| 2020-06-30 |
$-94 |
| 2020-03-31 |
$-88 |
| 2019-12-31 |
$-86 |
| 2019-09-30 |
$-84 |
| 2019-06-30 |
$-83 |
| 2019-03-31 |
$-81 |
| 2018-12-31 |
$-79 |
| 2018-09-30 |
$-77 |
| 2018-06-30 |
$-75 |
| 2018-03-31 |
$-73 |
| 2017-12-31 |
$-71 |
| 2017-09-30 |
$-71 |
| 2017-06-30 |
$-65 |
| 2017-03-31 |
$-64 |
| 2016-12-31 |
$-59 |
| 2016-09-30 |
$-57 |
| 2016-06-30 |
$-54 |
| 2016-03-31 |
$-51 |
| 2015-12-31 |
$-48 |
| 2015-09-30 |
$-45 |
| 2015-06-30 |
$-43 |
| 2015-03-31 |
$-39 |
| 2014-12-31 |
$-36 |
| 2014-09-30 |
$-33 |
| 2014-06-30 |
$-29 |
| 2014-03-31 |
$-26 |
| 2013-12-31 |
$-23 |
| 2013-09-30 |
$-21 |
| 2013-06-30 |
$-21 |
| 2013-03-31 |
|
| 2012-12-31 |
|
| 2012-09-30 |
|
| 2012-06-30 |
|
| 2011-12-31 |
$-18 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.007B |
$0.005B |
|
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|
